Key Points
- CEO Emily Leproust sold 41,570 Twist Bioscience shares at an average price of $151.98, generating approximately $6.32 million. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, leaving her with 770,729 shares.
- Twist Bioscience reported quarterly revenue of $118.38 million, up 23.2% year over year and above estimates, but its adjusted loss of $0.56 per share missed expectations. The company remains unprofitable, with a negative net margin of 31.66%.
- The stock opened at $153.10 and has received a Moderate Buy consensus rating from analysts, with eight Buy ratings and an average price target of $98.30. Institutional ownership also increased, including a major stake expansion by the California State Teachers’ Retirement System.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CEO Emily Leproust sold 41,570 shares of Twist Bioscience stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $151.98, for a total transaction of $6,317,808.60. Following the transaction, the chief executive officer directly owned 770,729 shares in the company, valued at approximately $117,135,393.42. The trade was a 5.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Twist Bioscience Stock Up 2.0%
Twist Bioscience stock opened at $153.10 on Friday. The business has a fifty day moving average of $105.88 and a two-hundred day moving average of $73.35. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The firm has a market cap of $9.60 billion, a P/E ratio of -68.96 and a beta of 2.14. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $155.44.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The company had revenue of $118.38 million for the quarter, compared to the consensus estimate of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm's revenue was up 23.2% compared to the same quarter last year. During the same period last year, the business posted $0.33 EPS. On average, analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.
Analyst Ratings Changes
TWST has been the subject of a number of recent research reports. Barclays boosted their target price on shares of Twist Bioscience from $65.00 to $95.00 and gave the stock an "overweight" rating in a report on Wednesday, June 24th. Piper Sandler raised their price target on shares of Twist Bioscience from $85.00 to $115.00 and gave the company an "overweight" rating in a report on Wednesday, August 5th. UBS Group set a $89.00 price objective on shares of Twist Bioscience in a research report on Monday, June 15th. TD Cowen reiterated a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Finally, Guggenheim reissued a "buy" rating on shares of Twist Bioscience in a research report on Monday. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $98.30.
View Our Latest Stock Report on Twist Bioscience
Institutional Investors Weigh In On Twist Bioscience
A number of large investors have recently modified their holdings of the business. Corient Private Wealth LP acquired a new position in shares of Twist Bioscience during the second quarter valued at about $2,226,000. Amundi purchased a new position in shares of Twist Bioscience in the 2nd quarter valued at approximately $252,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Twist Bioscience in the 2nd quarter worth approximately $1,640,000. California State Teachers Retirement System boosted its stake in Twist Bioscience by 10,945.7% in the 2nd quarter. California State Teachers Retirement System now owns 7,770,424 shares of the company's stock worth $799,421,000 after purchasing an additional 7,700,076 shares in the last quarter. Finally, AlphaGrep UK Ltd purchased a new stake in Twist Bioscience during the 2nd quarter worth approximately $229,000.
About Twist Bioscience
(
Get Free Report)
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
